Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of liraglutide on depressive status in patients with type 2 diabetes mellitus and major depressive disorder
ChiCTR2300074947Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: HAMD-17 score change. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300074947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074947.